-
2023-508112-35-00
4
2025-04-15
ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
-
2024-512901-22-00
5
2025-02-10
Acute Heart Failure
-
2025-520777-39-00
6
2025-01-29
Complicated acute appendicitis
-
2024-514656-32-00
4
2025-01-23
Suspected or confirmed Gram negative infections
-
2024-512161-14-00
3
2025-01-14
Breast Cancer
-
2024-513860-25-00
9
2024-12-10
Ovarian Neoplasms
-
2024-511465-11-00
5
2024-11-20
Spontaneous lobar ICH
-
2024-516777-77-00
4
2024-10-31
Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GE
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508258-24-00
4
2024-09-12
Ovarian cancer (OC) with oligometastatic progression (OMP).
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2024-511309-47-00
4
2024-07-17
moderate thrombocytopenia
-
2023-510536-37-00
4
2024-07-05
Prostate Cancer
-
2024-511959-18-01
5
2024-07-01
Acute Pulmonary Embolism
-
2024-511677-29-01
6
2024-06-20
BRONCHIECTASIA
-
2023-508316-27-00
6
2024-06-10
Patients with liver tumors that will undergo minimally invasive liver
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2024-511397-70-00
4
2024-05-06
metastatic renal cell carcinoma (mRCC)
-
2023-504374-38-00
5
2024-04-12
Locally advanced cervical cancer
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2024-512077-27-00
6
2024-04-04
NEUROCRITIC PATIENTS